Article Text

Download PDFPDF
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation
  1. M K de Vries1,
  2. G J Wolbink2,
  3. S O Stapel3,
  4. E R de Groot3,
  5. B A C Dijkmans4,
  6. L A Aarden3,
  7. I E van der Horst-Bruinsma5
  1. 1Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
  2. 2Sanquin Research, Amsterdam, The Netherlands
  3. 3Sanquin Research, Amsterdam, The Netherlands
  4. 4VU University Medical Center, Amsterdam, The Netherlands
  5. 5VU University Medical Center, Amsterdam, The Netherlands
  1. Correspondence to:
    Dr M K de Vries
    Department of Rheumatology, VU University Medical Centre, Room 4A-42, PO Box 7057, 1007 MB Amsterdam, The Netherlands; mk.devries{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Tumour necrosis factor blocking agents such as infliximab have proved to be effective in patients with ankylosing spondylitis as up to 60–70% of the patients meet the 20% response criteria of assessment in ankylosing spondylitis (ASAS).1,2 However, it cannot be explained why 30% of patients fail to respond and develop adverse reactions.

In rheumatoid arthritis, inefficacy to infliximab was associated with low serum trough infliximab levels and the presence of antibodies to infliximab (ATI).3

This study was designed to identify whether infliximab levels and ATI predict clinical inefficacy and adverse events in ankylosing spondylitis.

Eight patients with active ankylosing spondylitis (fulfilling the 1984 modified New York Criteria …

View Full Text


  • Competing interests: None declared.